Atai Life Sciences N.V. (ATAI)
ATAI Stock Price Chart
Explore Atai Life Sciences N.V. interactive price chart. Choose custom timeframes to analyze ATAI price movements and trends.
ATAI Company Profile
Discover essential business fundamentals and corporate details for Atai Life Sciences N.V. (ATAI) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
18 Jun 2021
Employees
54.00
Website
https://www.atai.lifeCEO
Srinivas G. Rao
Description
Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.
ATAI Financial Timeline
Browse a chronological timeline of Atai Life Sciences N.V. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 12 May 2026
Upcoming earnings on 12 Nov 2025
EPS estimate is -$0.11.
Earnings released on 14 Aug 2025
EPS came in at -$0.14 falling short of the estimated -$0.12 by -16.67%, while revenue for the quarter reached $719.00K .
Earnings released on 14 May 2025
EPS came in at -$0.15 surpassing the estimated -$0.19 by +21.05%, while revenue for the quarter reached $1.56M .
Earnings released on 17 Mar 2025
EPS came in at -$0.24 falling short of the estimated -$0.14 by -71.43%, while revenue for the quarter reached -$5.00K , missing expectations by -101.67%.
Earnings released on 13 Nov 2024
EPS came in at -$0.16 falling short of the estimated -$0.15 by -6.67%, while revenue for the quarter reached $40.00K , missing expectations by -84.00%.
Earnings released on 13 Aug 2024
EPS came in at -$0.36 falling short of the estimated -$0.17 by -111.76%, while revenue for the quarter reached $273.00K .
Earnings released on 15 May 2024
EPS came in at -$0.17 surpassing the estimated -$0.20 by +15.00%.
Earnings released on 28 Mar 2024
EPS came in at -$0.12 surpassing the estimated -$0.17 by +29.41%, while revenue for the quarter reached $18.00K , missing expectations by -90.53%.
Earnings released on 14 Nov 2023
EPS came in at -$0.14 surpassing the estimated -$0.20 by +30.00%, while revenue for the quarter reached $87.00K , missing expectations by -45.63%.
Earnings released on 10 Aug 2023
EPS came in at -$0.21 matching the estimated -$0.21, while revenue for the quarter reached $172.00K .
Earnings released on 11 May 2023
EPS came in at -$0.21 surpassing the estimated -$0.22 by +4.55%, while revenue for the quarter reached $37.00K , beating expectations by +270.00%.
Earnings released on 24 Mar 2023
EPS came in at -$0.28 falling short of the estimated -$0.23 by -21.74%, while revenue for the quarter reached $38.00K , missing expectations by -62.32%.
Earnings released on 10 Nov 2022
EPS came in at -$0.22 surpassing the estimated -$0.23 by +4.35%, while revenue for the quarter reached $24.00K , missing expectations by -78.18%.
Earnings released on 15 Aug 2022
EPS came in at -$0.24 falling short of the estimated -$0.22 by -9.09%, while revenue for the quarter reached $170.00K .
Earnings released on 16 May 2022
EPS came in at -$0.24 surpassing the estimated -$0.25 by +4.00%.
Earnings released on 30 Mar 2022
EPS came in at -$0.63 falling short of the estimated -$0.23 by -173.91%, while revenue for the quarter reached $230.00K , beating expectations by +1.36K%.
Earnings released on 15 Nov 2021
EPS came in at -$0.21 surpassing the estimated -$0.28 by +25.00%, while revenue for the quarter reached $266.00K , meeting expectations.
Earnings released on 16 Aug 2021
EPS came in at -$0.31 falling short of the estimated -$0.13 by -138.46%.
Earnings released on 27 May 2021
EPS came in at -$0.57 .
Earnings released on 31 Mar 2021
EPS came in at $0.00 , while revenue for the quarter reached $19.88M .
Earnings released on 30 Sept 2020
EPS came in at -$0.55 .
ATAI Stock Performance
Access detailed ATAI performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.